At the CIRSE 2026 conference, invited speaker Dr. Stephen Kee presented key updates on Syncromune's SYNC-T therapy, specifically focusing on the SV-102 platform. The innovative treatment approach combines image-guided cryolysis with intratumoral immunotherapy to target tumors directly.
During his presentation, Dr. Kee reviewed the underlying mechanism of action of the SV-102 therapy. He also summarized previously reported Phase 1 clinical findings and discussed the progress of the ongoing Phase 2 LEGION-100 trial.
Source Attribution: Article content originally reported by Syncromune. Read original story coverage on Syncromune →
